If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> NEUROLOGY<br /> ISSN 2054-4529 Vol 3.1 • August 2015 • emjreviews.com<br /> INSIDE<br /> Review of<br /> EAN 2015<br /> Berlin, Germany<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 4<br /> CONGRESS REVIEW........................................................................................................................................ 12<br /> • Review of the 1st Congress of the European Academy of Neurology held in Berlin,<br /> Germany, 20th-23rd June 2015<br /> BEST ABSTRACT AWARD WINNERS AT EAN 2015................................................................................ 27<br /> INTERVIEWS WITH EMJ NEUROLOGY EDITORIAL BOARD.................................................................. 32<br /> SYMPOSIUM REVIEW<br /> • NON-ORAL DRUG DE<a title="EMJ Neurology 3.1 2015 page 1" href="http://viewer.zmags.com/publication/9403c13c?page=1"> NEUROLOGY ISSN 2054-4529 </a> <a title="EMJ Neurology 3.1 2015 page 2" href="http://viewer.zmags.com/publication/9403c13c?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Neurology 3.1 2015 page 3" href="http://viewer.zmags.com/publication/9403c13c?page=3"> NEUROLOGY • AUTOMATED QUANTIFICATION OF STROK</a> <a title="EMJ Neurology 3.1 2015 page 4" href="http://viewer.zmags.com/publication/9403c13c?page=4"> Editorial Board Editor-in-Chief: Prof Lászlo V</a> <a title="EMJ Neurology 3.1 2015 page 5" href="http://viewer.zmags.com/publication/9403c13c?page=5"> Neurology Dr Marco Feligioni, Scientific Resea</a> <a title="EMJ Neurology 3.1 2015 page 6" href="http://viewer.zmags.com/publication/9403c13c?page=6"> European Medical Journal EMJ Neurology Vol 3.1 </a> <a title="EMJ Neurology 3.1 2015 page 7" href="http://viewer.zmags.com/publication/9403c13c?page=7"> Welcome Welcome to this year’s edition of EMJ </a> <a title="EMJ Neurology 3.1 2015 page 8" href="http://viewer.zmags.com/publication/9403c13c?page=8"> CHOOSE YOUR NEXT STEP TO HELPING MORE VEST</a> <a title="EMJ Neurology 3.1 2015 page 9" href="http://viewer.zmags.com/publication/9403c13c?page=9"> Foreword </a> <a title="EMJ Neurology 3.1 2015 page 10" href="http://viewer.zmags.com/publication/9403c13c?page=10"> MIGRAINE: THE SEVENTH DISABLER Frovatriptan i</a> <a title="EMJ Neurology 3.1 2015 page 11" href="http://viewer.zmags.com/publication/9403c13c?page=11"> EFFICACY IN THE TREATMENT OF MIGRAINE Migraine w</a> <a title="EMJ Neurology 3.1 2015 page 12" href="http://viewer.zmags.com/publication/9403c13c?page=12"> EAN ANNUAL CONGRESS 2015 MESSE BERLIN, BERLIN, G</a> <a title="EMJ Neurology 3.1 2015 page 13" href="http://viewer.zmags.com/publication/9403c13c?page=13"> Welcome to the European Medical Journal review o</a> <a title="EMJ Neurology 3.1 2015 page 14" href="http://viewer.zmags.com/publication/9403c13c?page=14"> EAN ANNUAL CONGRESS 2015 diseases are becoming m</a> <a title="EMJ Neurology 3.1 2015 page 15" href="http://viewer.zmags.com/publication/9403c13c?page=15"> H IGHLIGHTS Extra Resources Required</a> <a title="EMJ Neurology 3.1 2015 page 16" href="http://viewer.zmags.com/publication/9403c13c?page=16"> EAN ANNUAL CONGRESS 2015 preventative, diagnost</a> <a title="EMJ Neurology 3.1 2015 page 17" href="http://viewer.zmags.com/publication/9403c13c?page=17"> Various less or non-invasive neuro</a> <a title="EMJ Neurology 3.1 2015 page 18" href="http://viewer.zmags.com/publication/9403c13c?page=18"> EAN ANNUAL CONGRESS 2015 service providers of sp</a> <a title="EMJ Neurology 3.1 2015 page 19" href="http://viewer.zmags.com/publication/9403c13c?page=19"> witnessed the evidence suggesting that new</a> <a title="EMJ Neurology 3.1 2015 page 20" href="http://viewer.zmags.com/publication/9403c13c?page=20"> EAN ANNUAL CONGRESS 2015 Wealth Determines Age of</a> <a title="EMJ Neurology 3.1 2015 page 21" href="http://viewer.zmags.com/publication/9403c13c?page=21"> New Concepts in the Treatment of Multiple Scleros</a> <a title="EMJ Neurology 3.1 2015 page 22" href="http://viewer.zmags.com/publication/9403c13c?page=22"> EAN ANNUAL CONGRESS 2015 failure, loss of spe</a> <a title="EMJ Neurology 3.1 2015 page 23" href="http://viewer.zmags.com/publication/9403c13c?page=23"> “There are a number of new treatments in the pi</a> <a title="EMJ Neurology 3.1 2015 page 24" href="http://viewer.zmags.com/publication/9403c13c?page=24"> EAN ANNUAL CONGRESS 2015 The </a> <a title="EMJ Neurology 3.1 2015 page 25" href="http://viewer.zmags.com/publication/9403c13c?page=25"> who are already on medication,” said Dr Ana </a> <a title="EMJ Neurology 3.1 2015 page 26" href="http://viewer.zmags.com/publication/9403c13c?page=26"> EAN ANNUAL CONGRESS 2015 Dr Boris Radic, M</a> <a title="EMJ Neurology 3.1 2015 page 27" href="http://viewer.zmags.com/publication/9403c13c?page=27"> AWARD WINNERS AT EAN 2015 The </a> <a title="EMJ Neurology 3.1 2015 page 28" href="http://viewer.zmags.com/publication/9403c13c?page=28"> EAN ANNUAL CONGRESS 2015 Data describing the prog</a> <a title="EMJ Neurology 3.1 2015 page 29" href="http://viewer.zmags.com/publication/9403c13c?page=29"> with women in whom a predisposing condition for C</a> <a title="EMJ Neurology 3.1 2015 page 30" href="http://viewer.zmags.com/publication/9403c13c?page=30"> EAN ANNUAL CONGRESS 2015 controls. Compared </a> <a title="EMJ Neurology 3.1 2015 page 31" href="http://viewer.zmags.com/publication/9403c13c?page=31"> EUROIMMUN Medizinische Labordiagnostika AG Yo</a> <a title="EMJ Neurology 3.1 2015 page 32" href="http://viewer.zmags.com/publication/9403c13c?page=32"> EDITORIAL BOARD INTERVIEWS Nils Erik Gilhus Profe</a> <a title="EMJ Neurology 3.1 2015 page 33" href="http://viewer.zmags.com/publication/9403c13c?page=33"> government. The main reason for initiating </a> <a title="EMJ Neurology 3.1 2015 page 34" href="http://viewer.zmags.com/publication/9403c13c?page=34"> EDITORIAL BOARD INTERVIEWS In European countries</a> <a title="EMJ Neurology 3.1 2015 page 35" href="http://viewer.zmags.com/publication/9403c13c?page=35"> development of pathology when fed with a low- cal</a> <a title="EMJ Neurology 3.1 2015 page 36" href="http://viewer.zmags.com/publication/9403c13c?page=36"> EDITORIAL BOARD INTERVIEWS develop, but, unfor</a> <a title="EMJ Neurology 3.1 2015 page 37" href="http://viewer.zmags.com/publication/9403c13c?page=37"> progressed since you first began research in</a> <a title="EMJ Neurology 3.1 2015 page 38" href="http://viewer.zmags.com/publication/9403c13c?page=38"> EDITORIAL BOARD INTERVIEWS Giuseppe Lanza Departm</a> <a title="EMJ Neurology 3.1 2015 page 39" href="http://viewer.zmags.com/publication/9403c13c?page=39"> SUBSCRIBE Follow us: FREE TO OUR YOUTUBE CHA</a> <a title="EMJ Neurology 3.1 2015 page 40" href="http://viewer.zmags.com/publication/9403c13c?page=40"> NON-ORAL DRUG DELIVERY STRATEGIES: FR</a> <a title="EMJ Neurology 3.1 2015 page 41" href="http://viewer.zmags.com/publication/9403c13c?page=41"> AM-IMPAKT trial in patients with morning akinesia</a> <a title="EMJ Neurology 3.1 2015 page 42" href="http://viewer.zmags.com/publication/9403c13c?page=42"> Time to dyskinesia Proportion with no dyskinesia</a> <a title="EMJ Neurology 3.1 2015 page 43" href="http://viewer.zmags.com/publication/9403c13c?page=43"> development of PD. Alpha-synuclein pathology </a> <a title="EMJ Neurology 3.1 2015 page 44" href="http://viewer.zmags.com/publication/9403c13c?page=44"> Prof Stocchi described an ongoing study, the Time</a> <a title="EMJ Neurology 3.1 2015 page 45" href="http://viewer.zmags.com/publication/9403c13c?page=45"> As with all therapeutic interventions, Prof Stocc</a> <a title="EMJ Neurology 3.1 2015 page 46" href="http://viewer.zmags.com/publication/9403c13c?page=46"> of oral levodopa has a delayed onset of action an</a> <a title="EMJ Neurology 3.1 2015 page 47" href="http://viewer.zmags.com/publication/9403c13c?page=47"> These problems highlight the need to consid</a> <a title="EMJ Neurology 3.1 2015 page 48" href="http://viewer.zmags.com/publication/9403c13c?page=48"> with apomorphine injection. EQ-5D-3L is a patient</a> <a title="EMJ Neurology 3.1 2015 page 49" href="http://viewer.zmags.com/publication/9403c13c?page=49"> delay and impaired gastric emptying in Parki</a> <a title="EMJ Neurology 3.1 2015 page 50" href="http://viewer.zmags.com/publication/9403c13c?page=50"> apomorphine hydrochloride Britannia Pharmaceutica</a> <a title="EMJ Neurology 3.1 2015 page 51" href="http://viewer.zmags.com/publication/9403c13c?page=51"> HYPOTHALAMIC–PITUITARY ALTERATIONS IN PATIE</a> <a title="EMJ Neurology 3.1 2015 page 52" href="http://viewer.zmags.com/publication/9403c13c?page=52"> over 90% of cases affecting intrathoracic lymph n</a> <a title="EMJ Neurology 3.1 2015 page 53" href="http://viewer.zmags.com/publication/9403c13c?page=53"> The anterior pituitary failure can be assoc</a> <a title="EMJ Neurology 3.1 2015 page 54" href="http://viewer.zmags.com/publication/9403c13c?page=54"> logistical reasons and due to risk of infe</a> <a title="EMJ Neurology 3.1 2015 page 55" href="http://viewer.zmags.com/publication/9403c13c?page=55"> factor alpha (TNFα) plays an important role in th</a> <a title="EMJ Neurology 3.1 2015 page 56" href="http://viewer.zmags.com/publication/9403c13c?page=56"> neurosarcoidosis presenting as intractable headac</a> <a title="EMJ Neurology 3.1 2015 page 57" href="http://viewer.zmags.com/publication/9403c13c?page=57"> MANAGEMENT OF MALIGNANT MIDDLE CEREBRAL ART</a> <a title="EMJ Neurology 3.1 2015 page 58" href="http://viewer.zmags.com/publication/9403c13c?page=58"> No. 108 December 2008) and National Institute for</a> <a title="EMJ Neurology 3.1 2015 page 59" href="http://viewer.zmags.com/publication/9403c13c?page=59"> showing potential to improve clinical outcomes in</a> <a title="EMJ Neurology 3.1 2015 page 60" href="http://viewer.zmags.com/publication/9403c13c?page=60"> Table 1: Summary of the three pooled rando</a> <a title="EMJ Neurology 3.1 2015 page 61" href="http://viewer.zmags.com/publication/9403c13c?page=61"> of 0-2, with the majority having an mRS score of </a> <a title="EMJ Neurology 3.1 2015 page 62" href="http://viewer.zmags.com/publication/9403c13c?page=62"> imaging within 6 hours of symptom onset: A prospe</a> <a title="EMJ Neurology 3.1 2015 page 63" href="http://viewer.zmags.com/publication/9403c13c?page=63"> CLINICAL RELEVANCE OF CEREBRAL </a> <a title="EMJ Neurology 3.1 2015 page 64" href="http://viewer.zmags.com/publication/9403c13c?page=64"> Cerebral autoregulation consists of fast and slow</a> <a title="EMJ Neurology 3.1 2015 page 65" href="http://viewer.zmags.com/publication/9403c13c?page=65"> cerebrovascular reactivity occurred days late</a> <a title="EMJ Neurology 3.1 2015 page 66" href="http://viewer.zmags.com/publication/9403c13c?page=66"> 120 100 80 60 40 20 0 0.4 0.2 0 -0.2 -</a> <a title="EMJ Neurology 3.1 2015 page 67" href="http://viewer.zmags.com/publication/9403c13c?page=67"> Thus, the monitoring of cerebral auto-regulation </a> <a title="EMJ Neurology 3.1 2015 page 68" href="http://viewer.zmags.com/publication/9403c13c?page=68"> autoregulation in SICH and a better analysi</a> <a title="EMJ Neurology 3.1 2015 page 69" href="http://viewer.zmags.com/publication/9403c13c?page=69"> AUTOMATED QUANTIFICATION OF STROKE DAMAGE ON </a> <a title="EMJ Neurology 3.1 2015 page 70" href="http://viewer.zmags.com/publication/9403c13c?page=70"> a blood vessel in the brain becomes blocked by a </a> <a title="EMJ Neurology 3.1 2015 page 71" href="http://viewer.zmags.com/publication/9403c13c?page=71"> The overall inter-observer agreement of ASPECTS s</a> <a title="EMJ Neurology 3.1 2015 page 72" href="http://viewer.zmags.com/publication/9403c13c?page=72"> Figure 1: Automated scoring output of the </a> <a title="EMJ Neurology 3.1 2015 page 73" href="http://viewer.zmags.com/publication/9403c13c?page=73"> Rajini et al.27 looked for small infarcts (e.g. l</a> <a title="EMJ Neurology 3.1 2015 page 74" href="http://viewer.zmags.com/publication/9403c13c?page=74"> REFERENCES 1. Evers SM et al. Int</a> <a title="EMJ Neurology 3.1 2015 page 75" href="http://viewer.zmags.com/publication/9403c13c?page=75"> REPERFUSION STRATEGIES FOR ACUTE ISCHAEMIC ST</a> <a title="EMJ Neurology 3.1 2015 page 76" href="http://viewer.zmags.com/publication/9403c13c?page=76"> To avoid delays, implementation of stroke c</a> <a title="EMJ Neurology 3.1 2015 page 77" href="http://viewer.zmags.com/publication/9403c13c?page=77"> (ARTTS) trial argatroban has been combined w</a> <a title="EMJ Neurology 3.1 2015 page 78" href="http://viewer.zmags.com/publication/9403c13c?page=78"> ENDOVASCULAR TREATMENT The need for and developm</a> <a title="EMJ Neurology 3.1 2015 page 79" href="http://viewer.zmags.com/publication/9403c13c?page=79"> and lower mortality rates compared with standard </a> <a title="EMJ Neurology 3.1 2015 page 80" href="http://viewer.zmags.com/publication/9403c13c?page=80"> REFERENCES 1. Ferrell AS, Britz GW. Develop</a> <a title="EMJ Neurology 3.1 2015 page 81" href="http://viewer.zmags.com/publication/9403c13c?page=81"> 38. Albers GW et al. Magnetic resonance imaging p</a> <a title="EMJ Neurology 3.1 2015 page 82" href="http://viewer.zmags.com/publication/9403c13c?page=82"> UPDATE ON ALZHEIMER’S DISEASE </a> <a title="EMJ Neurology 3.1 2015 page 83" href="http://viewer.zmags.com/publication/9403c13c?page=83"> other dementias.7 MCI, being common in elderly pe</a> <a title="EMJ Neurology 3.1 2015 page 84" href="http://viewer.zmags.com/publication/9403c13c?page=84"> score of AD pathology that incorporates</a> <a title="EMJ Neurology 3.1 2015 page 85" href="http://viewer.zmags.com/publication/9403c13c?page=85"> Table 1: Definition of Alzheimer’s disease (AD) de</a> <a title="EMJ Neurology 3.1 2015 page 86" href="http://viewer.zmags.com/publication/9403c13c?page=86"> Table 2: Drug treatment of cognitive symptoms in </a> <a title="EMJ Neurology 3.1 2015 page 87" href="http://viewer.zmags.com/publication/9403c13c?page=87"> (ii) non-pharmacological treatment options su</a> <a title="EMJ Neurology 3.1 2015 page 88" href="http://viewer.zmags.com/publication/9403c13c?page=88"> pathological hallmark of AD and other tauopathies</a> <a title="EMJ Neurology 3.1 2015 page 89" href="http://viewer.zmags.com/publication/9403c13c?page=89"> 18. Veitinger M et al. A platelet protein biochip</a> <a title="EMJ Neurology 3.1 2015 page 90" href="http://viewer.zmags.com/publication/9403c13c?page=90"> 61. Salloway S et al. Two phase 3 trials of bapi</a> <a title="EMJ Neurology 3.1 2015 page 91" href="http://viewer.zmags.com/publication/9403c13c?page=91"> TREATMENT OF STATUS EPILEPTICUS – A NARRATIVE REV</a> <a title="EMJ Neurology 3.1 2015 page 92" href="http://viewer.zmags.com/publication/9403c13c?page=92"> differences were observed. This study also includ</a> <a title="EMJ Neurology 3.1 2015 page 93" href="http://viewer.zmags.com/publication/9403c13c?page=93"> the antiepileptic therapy <72 hours before </a> <a title="EMJ Neurology 3.1 2015 page 94" href="http://viewer.zmags.com/publication/9403c13c?page=94"> Non-convulsive SE in the postictal phas</a> <a title="EMJ Neurology 3.1 2015 page 95" href="http://viewer.zmags.com/publication/9403c13c?page=95"> REFERENCES 1. Rosenow F et al. The epidemiology </a> <a title="EMJ Neurology 3.1 2015 page 96" href="http://viewer.zmags.com/publication/9403c13c?page=96"> STATUS EPILEPTICUS IN CRITICALLY ILL PATIENTS </a> <a title="EMJ Neurology 3.1 2015 page 97" href="http://viewer.zmags.com/publication/9403c13c?page=97"> for 30 mins or more, the absence of overt clinica</a> <a title="EMJ Neurology 3.1 2015 page 98" href="http://viewer.zmags.com/publication/9403c13c?page=98"> derived from the patient’s clinical history </a> <a title="EMJ Neurology 3.1 2015 page 99" href="http://viewer.zmags.com/publication/9403c13c?page=99"> Table 1 continued. CLINICAL FEATURES EEG PA</a> <a title="EMJ Neurology 3.1 2015 page 100" href="http://viewer.zmags.com/publication/9403c13c?page=100"> Table 2: Management of status epilepticus. Immedi</a> <a title="EMJ Neurology 3.1 2015 page 101" href="http://viewer.zmags.com/publication/9403c13c?page=101"> an increased lactate/pyruvate ratio, can bring on</a> <a title="EMJ Neurology 3.1 2015 page 102" href="http://viewer.zmags.com/publication/9403c13c?page=102"> valproic acid, phenobarbital, levetiracetam</a> <a title="EMJ Neurology 3.1 2015 page 103" href="http://viewer.zmags.com/publication/9403c13c?page=103"> Table 3 continued. DRUG MECHANISMS OF ACTION INIT</a> <a title="EMJ Neurology 3.1 2015 page 104" href="http://viewer.zmags.com/publication/9403c13c?page=104"> Table 3 continued. DRUG MECHANISMS OF ACTION INIT</a> <a title="EMJ Neurology 3.1 2015 page 105" href="http://viewer.zmags.com/publication/9403c13c?page=105"> is considered useless; some patients need to be t</a> <a title="EMJ Neurology 3.1 2015 page 106" href="http://viewer.zmags.com/publication/9403c13c?page=106"> hypothyroidism in a critically ill patient. Inten</a> <a title="EMJ Neurology 3.1 2015 page 107" href="http://viewer.zmags.com/publication/9403c13c?page=107"> SIALORRHOEA: HOW TO MANAGE A FREQUENT COMPLICAT</a> <a title="EMJ Neurology 3.1 2015 page 108" href="http://viewer.zmags.com/publication/9403c13c?page=108"> of saliva clearance due to degeneration of both u</a> <a title="EMJ Neurology 3.1 2015 page 109" href="http://viewer.zmags.com/publication/9403c13c?page=109"> (i.e., falling head/chin) are the putative cause </a> <a title="EMJ Neurology 3.1 2015 page 110" href="http://viewer.zmags.com/publication/9403c13c?page=110"> Neurology (AAN) (2009) and the European</a> <a title="EMJ Neurology 3.1 2015 page 111" href="http://viewer.zmags.com/publication/9403c13c?page=111"> The main injection patterns found throughout</a> <a title="EMJ Neurology 3.1 2015 page 112" href="http://viewer.zmags.com/publication/9403c13c?page=112"> reported immediate and delayed side-effec</a> <a title="EMJ Neurology 3.1 2015 page 113" href="http://viewer.zmags.com/publication/9403c13c?page=113"> 2013;14(7-8):521-7. 13. Andersen PM et al. Good p</a> <a title="EMJ Neurology 3.1 2015 page 114" href="http://viewer.zmags.com/publication/9403c13c?page=114"> Would you like to write for the EMJ blog? Interac</a> <a title="EMJ Neurology 3.1 2015 page 115" href="http://viewer.zmags.com/publication/9403c13c?page=115"> Buyer’s Guide • ACTELION PHARMACEUTICALS LTD.</a> <a title="EMJ Neurology 3.1 2015 page 116" href="http://viewer.zmags.com/publication/9403c13c?page=116"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS, PUBL</a>